Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Reata Pharmaceuticals logo

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Key Stats

Today's Range
$172.36
$172.36
50-Day Range
$168.70
$172.36
52-Week Range
$21.83
$172.46
Volume
N/A
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RETA Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Headlines

RETA Stock Analysis - Frequently Asked Questions

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.32) by $0.35. The firm's quarterly revenue was up 428.6% compared to the same quarter last year.

Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reata Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Netflix (NFLX), Approach Resources (AREX) and Intel (INTC).

Company Calendar

Last Earnings
11/08/2021
Today
9/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RETA
CIK
1358762
Fax
N/A
Employees
321
Year Founded
2002

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$311.90 million
Net Margins
N/A
Pretax Margin
-373.40%
Return on Equity
-922.50%
Return on Assets
-73.39%

Debt

Debt-to-Equity Ratio
0.84
Current Ratio
3.21
Quick Ratio
3.19

Sales & Book Value

Annual Sales
$23.48 million
Price / Sales
280.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.79) per share
Price / Book
-96.29

Miscellaneous

Outstanding Shares
38,150,000
Free Float
27,926,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
1.42

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:RETA) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners